Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Boston Therapeutics, Inc. (BTHE) Takes Firm Stance Against Type 2 Diabetes, Backed by High-Potential Candidate Pipeline

Boston Therapeutics is developing a pipeline of therapeutic molecules based on complex carbohydrate chemistry. This pipeline currently carries three compounds that are being fine-tuned and tested in hopes that each will become a commercialized therapeutic treatment for diabetes.

Drug candidate PAZ320 is being developed for the prevention of diabetes and related complications. PAZ320 is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion. By blocking this release, the drug reduces the amount of available glucose absorbed through the intestine.

The company recently began enrollment for phase IIb trial in France to assess the efficacy and safety of PAZ320 in combination with metformin in patients with Type 2 diabetes. The company has also began preparation for an application of an investigational new drug (IND) submission to the U.S. FDA for phase III trial in the U.S., Europe, Hong Kong, and China to evaluate the effects of PAZ320 on post-meal glucose levels in patients with Type 2 diabetes.

In pre-clinical development is IPOXYN™, the company’s injectable therapeutic agent that utilizes proprietary processes and patented technology to prevent necrosis, the death of tissue from inadequate blood flow, and treatment of ischemic conditions that may result in necrosis. Necrosis is the outcome of severe and acute injury such as from pathological conditions such as heart attack, brain injuries and stroke, as well as neurodegenerative diseases such as Alzheimer’s disease, pancreatitis and many others. IPOXYN is targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

Aside from a gap in diabetes treatments in humans, Boston Therapeutics also recognizes the unmet need in the veterinary market for blood replacement and oxygen delivery due to damage or ischemic tissue as a result of trauma, surgery anemia or other disease conditions. For this application the company is developing OXYFEX™, which can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX is also in pre-clinical development.

Boston Therapeutics continues to advance its compounds to address the estimated 22 million people in the United States currently suffer from, and are enrolled in treatment for, Type 2 diabetes.

For more information, visit

Let us hear your thoughts below:

This entry was posted in Boston Therapeutics Inc. BTHE. Bookmark the permalink.

Comments are closed.